Indeed we and others demonstrated that cisplatin treatment leads to upregulation of ADAM17 and increased release of growth factors that mediate cisplatin resistance in ovarian cancer and hepatocellular carcinoma, respectively26,44. This evidence concerns the gene ADAM17 and ovarian cancer.